Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 37.9% on Thursday . The stock traded as high as C$0.24 and last traded at C$0.20. Approximately 1,160,600 shares were traded during trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Up 37.9 %
The firm’s fifty day moving average price is C$0.09 and its 200-day moving average price is C$0.07. The firm has a market cap of C$17.42 million, a price-to-earnings ratio of -10.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- How to Invest in the FAANG Stocks
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Comparing and Trading High PE Ratio Stocks
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
